IRIS
MAFFIOLI, PAMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.805
EU - Europa 4.646
AS - Asia 3.690
SA - Sud America 257
AF - Africa 31
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.445
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.704
CN - Cina 3.132
IE - Irlanda 1.175
UA - Ucraina 921
DE - Germania 658
FI - Finlandia 641
RU - Federazione Russa 491
SG - Singapore 396
SE - Svezia 254
IT - Italia 248
BR - Brasile 228
GB - Regno Unito 141
CA - Canada 79
FR - Francia 23
HK - Hong Kong 23
IN - India 23
NL - Olanda 21
IR - Iran 16
MX - Messico 13
TR - Turchia 13
ES - Italia 12
BE - Belgio 11
PE - Perù 10
TH - Thailandia 10
MU - Mauritius 9
AU - Australia 7
JO - Giordania 7
NZ - Nuova Zelanda 7
RO - Romania 7
UZ - Uzbekistan 7
DZ - Algeria 6
IQ - Iraq 6
ZA - Sudafrica 6
AT - Austria 5
CO - Colombia 5
EC - Ecuador 5
JP - Giappone 5
MY - Malesia 5
BD - Bangladesh 4
EE - Estonia 4
GR - Grecia 4
IL - Israele 4
KR - Corea 4
PK - Pakistan 4
PL - Polonia 4
PT - Portogallo 4
AR - Argentina 3
AZ - Azerbaigian 3
BH - Bahrain 3
CH - Svizzera 3
EG - Egitto 3
HU - Ungheria 3
KZ - Kazakistan 3
LV - Lettonia 3
MA - Marocco 3
OM - Oman 3
VE - Venezuela 3
AM - Armenia 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EU - Europa 2
GE - Georgia 2
KE - Kenya 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
PA - Panama 2
RS - Serbia 2
TN - Tunisia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
GT - Guatemala 1
HN - Honduras 1
IM - Isola di Man 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
MD - Moldavia 1
MK - Macedonia 1
NI - Nicaragua 1
NO - Norvegia 1
PH - Filippine 1
PS - Palestinian Territory 1
QA - Qatar 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
UY - Uruguay 1
Totale 14.445
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.326
Dublin 1.175
Chandler 1.053
Nanjing 999
Boardman 430
Nanchang 421
Ashburn 322
Shenyang 296
Hebei 283
Princeton 283
Lawrence 275
Medford 267
Wilmington 253
Changsha 248
Jiaxing 218
Hangzhou 170
Helsinki 153
Tianjin 144
Singapore 130
Beijing 109
Munich 99
Moscow 88
Toronto 69
Cambridge 54
Ann Arbor 53
Woodbridge 49
Milan 48
Shanghai 45
Seattle 44
Fairfield 33
Norwalk 33
Los Angeles 29
Des Moines 23
Hong Kong 23
Jinan 23
São Paulo 23
Kunming 21
Bruino 19
Pavia 19
Genova 17
Zhengzhou 16
Pune 14
Falkenstein 13
Orange 13
Piscataway 13
Guangzhou 12
New York 12
Ningbo 12
Brussels 9
Eindhoven 9
Lima 9
Belo Horizonte 8
West Jordan 8
Amman 7
Bangkok 7
Bologna 7
Fuzhou 7
Redwood City 7
Taizhou 7
Tashkent 7
Lanzhou 6
Leawood 6
Nuremberg 6
San Francisco 6
Washington 6
Auckland 5
Berlin 5
Bogotá 5
Campinas 5
Changchun 5
Dearborn 5
Houston 5
Paris 5
Redmond 5
Shah Alam 5
Alcobendas 4
Armidale 4
Baghdad 4
Buffalo 4
Cagliari 4
Dallas 4
Genoa 4
Halifax 4
Isernia 4
Kochi 4
Rio de Janeiro 4
Rotterdam 4
Shabestar 4
Suwon 4
São Bernardo do Campo 4
The Dalles 4
Tokyo 4
Verona 4
Vienna 4
Baku 3
Carpenedolo 3
Catania 3
Chicago 3
Guarulhos 3
Jyväskylä 3
Totale 9.738
Salva come PNG Salva come JPEG
Nome #
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial 199
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial 150
A randomized, placebo-controlled study about the effect of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 138
Diagnostico y Tratamiento de los desordenes lipidicos. Mc Graw Hill Education 2014. 97
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 89
Diarrea in paziente diabetico 88
A multicenter, randomised, single-blind study on the effects of exenatide or glimepiride on insulin resistance. 85
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 83
Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 83
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients 82
Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study 80
A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy 80
Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. 80
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 79
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 78
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 78
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load 77
Differenti effetti di candesartan e olmesartan sui parametri di attività del tessuto adiposo in pazienti diabetici di tipo 2 ipertesi 74
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus 72
Aerobic physical activity in obese subjects compared to anaerobic/aerobic physical activity 72
Adipocytokines levels in obese and non-obese subjects, an observational study 72
Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 72
Acarbose compared to placebo on insulin resistance biomarkers in a double-blind, placebo-controlled trial 71
Effects of berberine on lipid profile in subjects with low cardiovascular risk 71
Confronto tra candesartan e olmesartan sui parametri correlati alla sensibilità insulinica nei pazienti ipertesi con diabete mellito di tipo 2 71
n-3 PUFAs on metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients after euglycemic clamp and oral fat load. 70
A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. 70
A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients 69
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 69
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients 69
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin 68
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. 68
Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. 68
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis 68
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 67
Effects of sibutramine plus L-carnitine compared to sibutramine on inflammatory parameters in type 2 diabetic patients 67
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study 67
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study 66
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 66
Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. 66
Effetti di un anno di trattamento con vildagliptin associato a pioglitazone o glimepiride in pazienti diabetici scarsamente controllati 66
Effect of manidipine-rosuvastatin combination on fibrinolysis, inflammation markers and insulin sensitivity in hypertensive hypercholesterolemic patients 66
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus 66
A systematic reviewandmeta-analysis of randomized controlled trials investigating the effects of supplementationwith Nigella sativa (black seed) on blood pressure 66
Effetti di un anno di trattamento con orlistat+L-carnitina paragonato a orlistat o placebo sui parametri di insulino-resistenza nei pazienti diabetici 65
Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial. 65
A clinical trial about a food supplement containing α-lipoic acid on oxidative stress markers in type 2 diabetic patients 65
Candesartan effect on inflammation in hypertension 64
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients 64
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 64
Prevalence of erectile dysfunction in males affected by type 2 diabetes and the impact of hyperinsulinemia 64
Valutazione dell’infiammazione e delle MMPs nei soggetti con e senza diabete durante OGTT 64
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 64
Hypoglycemia, its implications in the clinical practice, and possible ways to prevent it. 64
Anti-obesity drugs: a review about their effects and their safety 63
Impact of the glyco-metabolic control on erectile dysfunction in patients with type 2 diabetes mellitus 63
Effetti di un carico lipidico orale sui marcatori di infiammazione e stress endoteliale nei soggetti sani 63
Prevalence and associations of erectile dysfunction in a sample of italian males with type 2 diabetes. 63
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients 62
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia during omega-3 polyunsaturated fatty acids therapy 62
Metformina in bustine rispetto a metformina nella classica formulazione in compresse: primi risultati di uno studio clinico 62
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 62
Effetti sulla variabilità glicemica e sul compenso glico-metabolico di metformina, pioglitazone e sitagliptin in pazienti affetti da diabete mellito di tipo 2 62
Valutazione dei livelli di metalloproteasi 2 e 9 e dei loro inibitori nei soggetti con dislipidemia combinata 61
Sitagliptin in aggiunta alla precedente terapia ipoglicemizzante sull'insulino-resistenza e il profilo lipidico: uno studio a due anni 61
A curious case of hypoglycaemia 61
Pharmacotherapy for Obesity 61
Matrix metalloproteinase-2 and – 9 levels in obese patients 60
Effetti di un carico lipidico orale sui marcatori di rimodellamento vascolare nei soggetti sani 60
Rosiglitazone maleate and glimepiride in fixed combination for the metabolic control of type 2 diabetes 60
Effetti di un anno di trattamento con exenatide paragonato a glibenclamide in pazienti diabetici di tipo 2 60
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 60
Effects of thiazolidinediones and sulfonylureas in patients with diabetes 59
Evaluation of candesartan compared to olmesartan on insulin sensitivity-related parameters in type 2 diabetic hypertensive patients 59
Pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina durante un carico orale di grassi 59
Effetto del telmisartan sui marcatori infiammatori a digiuno e postprandiale nei pazienti diabetici ipertesi 59
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study 58
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes 58
Effect of acarbose on inflammatory parameters at baseline and after an oral fat load: a double-blind, placebo controlled trial 58
Exenatide or glimepiride on insulin resistance in type 2 diabetic patients 58
Effetti della combinazione Berberis aristata/Silybum marianum sul profilo lipidico e la secrezione insulinica in pazienti con basso rischio cardiovascolare 58
Caso clinico: efficacia e sicurezza di exenatide LAR in un paziente diabetico obeso tipo 2. 58
Safety and efficacy of albiglutide-results from two trials 58
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 58
Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. 58
Effetti di sitagliptin o metformina associati a pioglitazone in pazienti diabetici scarsamente controllati 58
A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus 58
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 57
Current and emerging pharmacotherapies for the management of hypertension, focus on aliskiren 57
Evaluation of candesartan compared to olmesartan on insulin-sensitivity related parameters in type 2 diabetic hypertensive patients 57
Valutazione dei livelli delle metalloproteasi 2 e 9 e dei loro inibitori nella dislipidemia combinata durante terapia con acidi grassi polinsaturi 57
Glycemic excursions and variations of some inflammatory indices in patients with end-stage renal disease with and without type 2 diabetes mellitus undergoing two different dialysis techniques 57
Effects of exenatide + metformin combination on some adipocytokines levels: a comparison with metformin monotherapy 57
Effetti della formulazione idrosolubile di metformina sul compenso glicemico e sulla qualità della vita in pazienti con diabete mellito di tipo 2 57
Effects of an olmesartan/amlodipine combination compared to olmesartan or amlodipine monotherapies on some insulin resistance parameters in hypertensive patients 57
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 57
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria 57
Effetti di una combinazione di un estratto di berberis aristata/silybum marianum sul profilo lipidico e la secrezione insulinica in pazienti dislipidemici 57
Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients 57
Comparison of orlistat treatment and placebo in obese type 2 diabetic patients 56
Totale 6.866
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.804
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.804
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020343 0 0 0 0 0 0 0 0 0 300 43 0
2020/20211.754 221 170 39 176 2 217 8 319 46 286 225 45
2021/20221.031 9 4 65 9 4 6 8 58 59 7 175 627
2022/20233.250 358 193 6 221 372 348 2 198 1.370 40 94 48
2023/20241.058 120 196 37 73 121 257 16 120 9 33 37 39
2024/20251.999 24 329 98 110 70 89 246 284 718 31 0 0
Totale 14.785